Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, SwitzerlandGlobeNewsWire • 05/20/21
Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing ResearchGlobeNewsWire • 05/13/21
Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a DataGlobeNewsWire • 05/12/21
Biogen, Capsigen Ink $1.3B AAV Capsids Development Pact For CNS & Neuromuscular DisordersBenzinga • 05/11/21
Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular DisordersGlobeNewsWire • 05/10/21
Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 EndBenzinga • 05/03/21
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)GlobeNewsWire • 04/28/21
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance MetricsGlobeNewsWire • 04/28/21
Jefferies Top Value Stocks to Buy May Have Momentum Stock Upside Potential24/7 Wall Street • 04/27/21
Biogen Inc. (BIIB) CEO Michel Vounatsos on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/22/21
Biogen talks up approval plans for controversial Alzheimer's drug as it nears FDA decisionMarket Watch • 04/22/21
Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera SalesBenzinga • 04/22/21